# Bioequivalence Study of the Second Generation Dutasteride and Tamsulosin HCl Combination Capsule in Fed State

> **NCT02058576** · PHASE1 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 77 (actual)

## Conditions studied

- Urologic Diseases

## Interventions

- **DRUG:** Commercially available combination of dutasteride 0.5 mg and tamsulosin HCL 0.4 mg
- **DRUG:** Second generation dutasteride 0.5 mg and tamsulosin HCL 0.4 mg combination capsule

## Key facts

- **NCT ID:** NCT02058576
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-02-11
- **Primary completion:** 2015-01-02
- **Final completion:** 2015-01-02
- **Target enrollment:** 77 (ACTUAL)
- **Last updated:** 2018-09-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02058576

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02058576, "Bioequivalence Study of the Second Generation Dutasteride and Tamsulosin HCl Combination Capsule in Fed State". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02058576. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*